PK/PD modeling
Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling
... (PK/PD) modeling (5–7). PK/PD modeling was successfully applied for the selec- tive dopamine D2 antagonist remoxipride, both in human (8) and rat (9), to predict the ...
12
Don't be afraid! Population PK-PD modeling as the basis for individualized dosing in children and critically ill
... and PK or PD model parameters, using fixed effects ...the modeling of the distribution of the individual parameter estimates as a function of patient characteristics ...the PK and/or ...
155
Systems Pharmacology: Defining the Interactions of Drug Combinations
... and PD models that integrate molecular-level events with higher time scales and treatment response ...integrated PK-PD modeling with a model of the vascu- lar endothelial growth factor ...
24
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients
... using PK–PD ...drug PK and PD and the involvement of monocytes is of the utmost importance because the nonlinear PK of the liposomal drug may be explained by the saturation of ...
10
Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK PD model: study protocol for a PK PD trial
... uses PK-PD modeling to provide a description of the concentration – effect relationship and an estimate of pharmacological potency of the ...the PK-PD characteristics of the combination ...
8
A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004
... (PK/PD) modeling based on Monte Carlo simulations can be used reliably to predict the ability of antimicrobial regimens to achieve maximum bactericidal effect against organisms implicated in ...
6
Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
... In all but one patient (14 out of 15), the absolute neutro- phil count (ANC) was the dose-limiting factor through- out all cycles. During the cycles in which IDT was performed, the median ANC nadir observed was 1100/ mm ...
9
Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers
... Although mitiglinide is a commonly used and effective drug for diabetes mellitus in clinic, its side effects and the interaction remain to be studied further. A recent in- vestigation shows that mitiglinide treatment ...
8
Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics
... with PK/PD modeling has been shown in a few ...complex PK/PD model that described the gene-expression signaling cascade in the rat liver after corticosteroid treatment ...the ...
13
Population Pharmacokinetic Pharmacodynamic Modeling of Caffeine Using Visual Analogue Scales
... population PK-PD model for VAS data after oral administration of caffeine beve- ...rages. Modeling was conducted with NONMEM ® (ICON, Ellicott City, Maryland, version ...sequential ...
11
Pharmacokinetic Pharmacodynamic modeling of the analgesic effect of bupredermTM, in mice
... which PK-PD dosing parameter best correlates with treatment outcomes ...of PK-PD modeling is of par- ticular importance to optimize drug use by designing rational dosage forms and ...
8
Development and Validation of Pharmacokinetic (PK) and Pharmacodynamic (PD) models of certain new formulations.
... then, PK/PD of opioids have been repeatedly assessed, using EEG derived parameters, pupil size, and experimental and clinical pain as effect ...their PK/PD ...h. PK/PD ...
164
Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects
... sequential modeling approach was applied and indi- vidual post hoc Bayesian estimates of the developed PK model were added to the PD ...with PK model ...
8
Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing
... the PK–PD relationship for RIF’s increasing doses, and how conventional PK–PD analyses might fall short of explaining rather complex dynamics that change over time, as well as the possibility ...
13
A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model
... cellular PK/PD model, as well as provided a method for designing or optimizing prophylactic dos- age regimens for voriconazole in high-risk immunosup- pressed patients based on Monte Carlo simulation and ...
9
Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon<sup>®</sup> and Eprex<sup>®</sup> following a single subcutaneous administration in healthy male volunteers
... the PD and tolerability profiles were similar between the two ...and PD markers presented a counterclockwise hysteresis, suggesting a time delay between the mea- sured concentration and the ...
9
Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections
... the PK–PD of the antimicrobial agent as well as the patients’ co-morbidities and the severity of ...the PK data used in the analysis were obtained from a Caucasian population, the extrapola- tion of ...
6
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
... This study has a number of limitations. First of all, this study did not look at clinical outcomes as the data were drawn from PK studies. Logically, clinical cure and mortal- ity should be investigated in future ...
9
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam
... the PK-PD parameter of interest is the percentage of time in a dosage interval for which drug concentrations remain above the minimum inhibitory concentration (MIC) of the infecting ...the ...
7
<p>Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation</p>
... a PK or PD interacting medication with apixaban was calculated by dividing the number of patients who received a PK or PD interacting medication with apixaban by the total number of patients ...
9